Fig. 4From: Impact of the COVID-19 pandemic in childhood and adolescent cancer care in northern Tanzania: a cross-sectional studyDistribution of diagnosis by site groups and across stage before and during COVID-19 (n = 167). Notes Group I: Leukemias, myeloproliferative diseases, myelodysplastic diseases; Group II: Lymphomas and reticuloendothelial neoplasms; Group III: CNS and miscellaneous intracranial and intraspinal neoplasms; Group IV: Neuroblastoma and other peripheral nervous cell tumors; Group V: Retinoblastoma; Group VI: Renal tumors; Group VII: Hepatic tumors; Group VIII: Malignant bone tumors, Group IX: Soft tissue and other extraosseous sarcomas; Group X: Germ cell tumors, trophoblastic tumors, and neoplasms of gonads; Group XI: Other malignant epithelial neoplasms and malignant melanomas; Group XII: Other and unspecified malignant neoplasmsBack to article page